Protein Plus: Improving Infant Growth Through Diet and Enteric Health
Model scores of the 29,894 trials active now.
Model score 7% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (81 trials).
Finished trial that started in 2015 or later: the model never saw it during training.
How it ended
Completed on 2020-03-24, after 2018-09-23 start.
The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-03-24. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Sponsor's past termination rate: 3.4% (lowers risk) · Sponsor's track record
-
Design: factorial (lowers risk) · Design
-
Accepts healthy volunteers: No (raises risk) · Who can join
-
Primary purpose: prevention (lowers risk) · Design
-
Blinding: quadruple (lowers risk) · Design
-
Number of arms: 8 (lowers risk) · Design
-
Disease area, cancer: No (lowers risk) · Disease area
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: growthongoinghighwomeninfants
Phrases that lowered it: periodintakeefficacyold12 -
Trials the sponsor started in the prior 2 years: 32 (lowers risk) · Sponsor's track record
-
Drug's FAERS reports with a death: 8.4% (lowers risk) · Drug's FDA history
-
Minimum age: 0.25 (lowers risk) · Who can join
-
Has a data monitoring committee: Yes (raises risk) · Design
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Drug's FAERS reports marked serious: 69.5% (lowers risk) · Drug's FDA history
-
Sponsor's past trials: 149 (lowers risk) · Sponsor's track record
-
Phase: 2/3 (raises risk) · Design
-
Disease area, infectious disease: Yes (lowers risk) · Disease area
-
Maximum age: 0.5 (raises risk) · Who can join
-
Collaborators: 2 (lowers risk) · Design
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 2/3 (typical: 2)
- Number of arms
- 8 (typical: 2)
- Allocation
- randomized
- Design
- factorial (typical: parallel)
- Primary purpose
- prevention (typical: treatment)
- Blinding
- quadruple (typical: none)
- Has a data monitoring committee
- Yes (typical: 56% yes)
- Responsible party
- sponsor
- Collaborators
- 2 (typical: 0)
- Keywords listed
- 3 (typical: 1)
Who can join
- Minimum age
- 0.25 (typical: 18)
- Maximum age
- 0.5 (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 149 (typical: 32)
- Sponsor's past termination rate
- 3.4% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 32 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 1
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 37783 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 7474 (typical: 412.5)
- Drug's FAERS reports marked serious
- 69.5% (typical: 85.6%)
- Drug's FAERS reports with a death
- 8.4% (typical: 15.9%)
Disease area and drugs
- Disease areas
- infectious disease, metabolic
- Drugs matched to FDA substances
- azithromycin
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Use of Probiotics to Reduce Infections, Death and ESBL Colonisation NCT04172012 · started 2022 · scored riskier than 4% of active trials completed
- Azithromycin for Uncomplicated Severe Acute Malnutrition in Burkina Faso (Pilot) NCT03568643 · started 2020 · scored riskier than 27% of active trials completed
- Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old NCT03474276 · started 2018 · scored riskier than 5% of active trials completed
- Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger NCT02145000 · started 2014 · scored riskier than 1% of active trials completed
- Optimizing the Management of Acute Diarrhoeal Disease NCT02803827 · started 2016 · scored riskier than 30% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.